Chen Jun, Jiang Qian, Zhang Yu, Yu Yufei, Zheng Yifeng, Chen Juan, Zhao Yiqing, Miao Zhuangzhuang, Fan Fanfan, Wang Yu
Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Operating room, Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
World Neurosurg. 2019 Feb;122:e1606-e1614. doi: 10.1016/j.wneu.2018.11.151. Epub 2018 Nov 26.
Primary intracranial Ewing sarcoma (ES)/peripheral primitive neuroectodermal tumors (pPNETs) are extremely rare, and only a few studies have reported >4 cases of this disease. The purpose of this study was to explore the clinical features, treatment, and outcome of primary intracranial ES/pPNETs.
The clinical data of 14 patients who had been surgically treated from February 2003 to November 2017 and in whom immunohistochemical staining results had confirmed the diagnosis of primary intracranial ES/pPNETs were retrospectively analyzed. Kaplan-Meier survival analysis was used to estimate the survival rate and the median survival time (MST).
Gross total resection (GTR) was achieved in 7 cases, and subtotal resection was performed in 7 cases. During follow-up, 10 (71.4%) patients had local recurrence and 3 (21.4%) patients had distant metastasis. The overall 1-, 2-, and 5-year survival rates were 78.6%, 47.6%, and 19.0%, respectively. Kaplan-Meier survival analysis showed that postoperative radiotherapy was a significant prognostic factor for longer MST (P = 0.034). GTR and radiotherapy with or without adjuvant chemotherapy yielded the highest 2-year survival rate (100%). Three patients who underwent GTR, radiotherapy, and chemotherapy had the highest 2-year survival rates (100%) and the longest MST (48 months).
Primary intracranial ES/pPNETs have an aggressive clinical course, with a high tendency for local recurrence and distant metastasis. Radiotherapy plays a significant role in improving the survival of patients. GTR combined with radiotherapy and chemotherapy may be the most beneficial treatment modality.
原发性颅内尤因肉瘤(ES)/外周原始神经外胚层肿瘤(pPNETs)极为罕见,仅有少数研究报道过4例以上该疾病患者。本研究旨在探讨原发性颅内ES/pPNETs的临床特征、治疗方法及预后。
回顾性分析2003年2月至2017年11月期间接受手术治疗且免疫组化染色结果确诊为原发性颅内ES/pPNETs的14例患者的临床资料。采用Kaplan-Meier生存分析法评估生存率及中位生存时间(MST)。
7例实现了全切除(GTR),7例行次全切除。随访期间,10例(71.4%)患者出现局部复发,3例(21.4%)发生远处转移。1年、2年和5年总生存率分别为78.6%、47.6%和19.0%。Kaplan-Meier生存分析显示,术后放疗是MST延长的显著预后因素(P = 0.034)。GTR联合放疗(无论是否联合辅助化疗)的2年生存率最高(100%)。3例接受GTR、放疗及化疗的患者2年生存率最高(100%)且MST最长(48个月)。
原发性颅内ES/pPNETs临床病程侵袭性强,局部复发和远处转移倾向高。放疗对提高患者生存率起重要作用。GTR联合放疗及化疗可能是最有益的治疗方式。